Compare Biogen Inc (BIIB) vs Core Scientific Inc (CORZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Core Scientific Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Core Scientific Inc trades at $20.93 (market cap $6.35B). The key difference: Biogen Inc is far larger — about 4.7× Core Scientific Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | CORZ | |
|---|---|---|
Market Cap | $30.13B | $6.35B |
Sector | Health | Technology |
52-Week High | $216.63 | $29.16 |
52-Week Low | $128.93 | $13.55 |
Enterprise Value | $37.20B | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Core Scientific (CORZ) trades at $20.87, up 7.36% today, amid strong analyst support with 19 buy ratings and a $35.88 consensus price target. The stock shows bearish technical signals with resistance at $21, while fundamentals reveal significant losses (-$288.62M net income in 2025) despite revenue growth to $319M. Recent AMD partnership for 2.5GW data center capacity signals strategic pivot to AI infrastructure.
Outlook balances high growth potential from AI contracts against substantial cash burn and negative margins. Key risks include execution of expansion plans and profitability timeline, but institutional interest and analyst optimism suggest upside if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →
